TY - JOUR
T1 - Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP
AU - Strati, Paolo
AU - Fowler, Nathan
AU - Pina-Oviedo, Sergio
AU - Medeiros, L. Jeffrey
AU - Overman, Michael J.
AU - Romaguera, Jorge E
AU - Nastoupil, Loretta
AU - Wang, Michael
AU - Hagemeister, Fredrick B
AU - Rodriguez, Alma
AU - Oki, Yasuhiro
AU - Westin, Jason
AU - Turturro, Francesco
AU - Neelapu, Sattva S.
AU - Fayad, Luis
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/1
Y1 - 2018/1
N2 - The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. We analyzed 45 patients with FLG3 treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). R-CHOP showed to be an effective first-line treatment for these patients, and provided extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease. Background The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. Patients and Methods This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval. Results The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph >4 node sites and presence of B symptoms. Three patients later progressed to diffuse large B cell lymphoma, all had baseline elevated serum lactate dehydrogenase level and high International Prognostic Index score. Median overall survival has not been reached. All 4 patients who later developed acute myeloid leukemia were older than 60 years at the time of start of therapy. Conclusion R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
AB - The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. We analyzed 45 patients with FLG3 treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). R-CHOP showed to be an effective first-line treatment for these patients, and provided extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease. Background The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. Patients and Methods This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval. Results The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph >4 node sites and presence of B symptoms. Three patients later progressed to diffuse large B cell lymphoma, all had baseline elevated serum lactate dehydrogenase level and high International Prognostic Index score. Median overall survival has not been reached. All 4 patients who later developed acute myeloid leukemia were older than 60 years at the time of start of therapy. Conclusion R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
KW - FLG3
KW - Prognosis
KW - R-CHOP
KW - Survival
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85035220094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035220094&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2017.11.001
DO - 10.1016/j.clml.2017.11.001
M3 - Article
C2 - 29196178
AN - SCOPUS:85035220094
SN - 2152-2650
VL - 18
SP - e103-e108
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 1
ER -